v3.26.1
Acquisitions (Tables)
 6 Months Ended
Jun. 30, 2026
Evergreen Theragnostics  
Business Combination [Line Items]  
Summary of Acquisition Date Fair Value of Provisional Consideration Transferred in Acquisition

The acquisition date fair value of the consideration transferred in the Evergreen Acquisition consisted of the following (in thousands):

 

(in thousands)

 

 

 

Cash consideration

 

$

276,424

 

Fair value of contingent consideration

 

 

43,042

 

Total purchase consideration

 

$

319,466

 
Summary of Fair Value of Assets Acquired and Liabilities Assumed The following table summarizes the final fair value of assets acquired and liabilities assumed as of the date of acquisition:

 

(in thousands)

 

Estimated Fair Value

 

Assets acquired:

 

 

 

Cash and cash equivalents

 

$

8,065

 

Accounts receivable, other(1)

 

 

2,758

 

Prepaid expenses and other current assets

 

 

459

 

Property, plant and equipment, net

 

 

16,711

 

Intangibles(2)

 

 

215,000

 

Deferred tax assets

 

 

18,112

 

Other long-term assets

 

 

1,424

 

Total identifiable assets acquired

 

$

262,529

 

Liabilities assumed:

 

 

 

Accounts payable

 

$

(1,964

)

Accrued expenses and other current liabilities

 

 

(754

)

Deferred tax liabilities

 

 

(55,718

)

Other long-term liabilities

 

 

(848

)

Total liabilities assumed

 

 

(59,284

)

Net assets acquired

 

$

203,245

 

Purchase consideration

 

$

319,466

 

Goodwill(3)

 

$

116,221

 

 

(1)
The value approximates the gross contractual amount of accounts receivables. The contractual amount not expected to be collected is immaterial.
(2)
Intangible assets acquired consisted of in-process research and development (“IPR&D”). The estimated fair values of the IPR&D assets were determined based on the present values of the expected cash flows to be generated by the respective underlying assets. The
Company used a discount rate of 11.5% and cash flows that have been probability adjusted to reflect the risks of product commercialization, which the Company believes are appropriate and representative of market participant assumptions.
(3)
The goodwill recognized is attributable to future technologies that are not separately identifiable that could potentially add to the currently developed and pipeline products and Evergreen’s assembled workforce. Future technologies did not meet the criteria for recognition separately from goodwill because they are part of the future development and growth of the business. Goodwill of $116.2 million recognized in connection with the Evergreen Acquisition is not deductible for tax purposes.
Lantheus Biosciences Ltd  
Business Combination [Line Items]  
Summary of Acquisition Date Fair Value of Provisional Consideration Transferred in Acquisition

The acquisition date fair value of the provisional consideration transferred in the LMI Acquisition consisted of the following:

 

(in thousands)

 

Preliminary Estimate

 

 

Measurement Period Adjustment

 

 

Final

 

Cash consideration

 

$

355,204

 

 

$

(2,590

)

 

$

352,614

 

Fair value of contingent consideration

 

 

27,000

 

 

 

—

 

 

 

27,000

 

Total purchase consideration

 

$

382,204

 

 

$

(2,590

)

 

$

379,614

 
Summary of Fair Value of Assets Acquired and Liabilities Assumed The following table summarizes the fair values of assets acquired and liabilities assumed as of the date of acquisition:

(in thousands)

 

Estimated Fair Value

 

Assets acquired:

 

 

 

Cash and cash equivalents

 

$

46,193

 

Accounts receivable, other(1)

 

 

25,123

 

Inventory

 

 

1,125

 

Prepaid expenses and other current assets

 

 

1,974

 

Property, plant and equipment, net

 

 

4,979

 

Intangibles(2)

 

 

394,000

 

Deferred tax assets

 

 

15,993

 

Other long-term assets

 

 

11,506

 

Total identifiable assets acquired

 

$

500,893

 

Liabilities assumed:

 

 

 

Accounts payable

 

$

(5,715

)

Accrued expenses and other current liabilities

 

 

(25,964

)

Deferred tax liabilities

 

 

(72,570

)

Other long-term liabilities

 

 

(79,904

)

Total liabilities assumed

 

 

(184,153

)

Net assets acquired

 

$

316,740

 

Purchase consideration

 

$

379,614

 

Goodwill(3)

 

$

62,874

 

 

(1)
The value approximates the gross contractual amount of accounts receivables. The contractual amount not expected to be collected is immaterial.
(2)
Intangible assets acquired consisted of IPR&D and currently marketed products. The estimated fair values of the IPR&D and currently marketed product assets were determined based on the present values of the expected cash flows to be generated by the respective underlying assets. The Company used a discount rate of 23.5% and 23.0% for IPR&D and currently marketed products, respectively. IPR&D cash flows have been probability-adjusted to reflect the risks of technical and regulatory success of the products, which the Company believes are appropriate and representative of market participant assumptions. The Company estimates that the acquired currently marketed product asset has a useful life of 10.5 years.
(3)
The goodwill recognized is attributable to future technologies that are not separately identifiable that could potentially add to the currently developed and pipeline products and Lantheus Biosciences’s assembled workforce. Future technologies did not meet the criteria for recognition separately from goodwill because they are part of the future development and growth of the business. Goodwill of $62.9 million recognized in connection with the LMI Acquisition is not deductible for tax purposes.